Skip to main content
Home
  • Solutions
    Clinical solutions
    Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Medical Imaging Site & Patient Solutions Strategic Solutions
    Consulting & Commercial
    Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Intelligence Regulatory Affairs Symphony Health data
    meeting
    Case studies

    Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

    Innovative research tools showcase
    Technologies

    Technology solutions from early phase through to post-marketing.

  • Sectors
    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Biotech Government and Public Health Medical Device Pharmaceuticals
    Biotechnology services navigation panel
    Biotech

    Developing transformative therapies requires a flexible approach.

    Employee engagement program overview
    ICON and You

    Partners making a difference.

  • Therapeutics
    Therapeutics
    Cardiovascular Central Nervous System Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology
    Cross-therapeutics
    Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health
    Obesity 2025 insights image
    Obesity

    A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.

    Biological research visual element
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Insights
    Insights
    Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel
    thumbnail
    Making sense of the rapidly changing biosimilars landscape

    Strategies for adapting and achieving optimal market access

    thumbnail
    Building a comparative evidence base using network meta-analysis

    Methods, implementation and reporting

    FSA_thumbnail
    From bottlenecks to breakthroughs

    Human-centred strategies for faster study starts

  • News & Events
    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    Press releases In the News Mediakit Awards Events Webinars Social media
    oligonucleotides
    Insights into first-in-human study design of oligonucleotides

    27 May 2026. Register now.

    webinar
    When patients lead: Breaking barriers in ultra-rare disease drug development

    Watch the webinar.

  • About ICON
    About ICON
    Company history ICON at a glance ICON in Asia Pacific ICON in Latin America Leadership Quality
    ICON for
    Patients Volunteers Investigators Jobs & Careers Investors Suppliers
    Responsible business practice indicators
    Sustainability, charity, inclusion and belonging

    ICON Cares is our commitment to making a positive impact on our people, environment and our community.

    Modern reception area at Dublin office
    ICON at a glance

    Delivering successful outcomes across the clinical development lifecycle.

  • Careers
  • Investors
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. News & Events
  3. Social media

Social media

Page tools
Share Share
Facebook

Share on Facebook

Facebook

Share on X

Facebook

Share on Linkedin

Bluesky

Share on Bluesky

ICON Plc facebook post
ICON Plc logo
ICON Plc

ICON is excited to sponsor RAPS Euro Convergence 2026, taking place 5–8 May in Lisbon. Visit us at booth #21 to meet our team and discuss how ICON combines expertise and experience with the latest in productivity tools...

14 Apr
8
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

Clinical research is evolving at pace and so is the role of the Clinical Research Associate. From increased use of technology and data, to more strategic site partnerships, today’s CRA plays a critical role in deliverin...

14 Apr
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

New methods for gathering long-term data are emerging through the use of RWD and tokenisation, providing new options for vaccine follow-up strategies. Find out what developers should ask to determine if these new strateg...

14 Apr
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

New methods for gathering long-term data are emerging through the use of RWD and tokenisation, providing new options for vaccine follow-up strategies. Find out what developers should ask to determine if these new strateg...

14 Apr
3
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

On 15 April at 12:00 pm, join ICON’s Alan Baldridge at the GLP-1-Based Therapeutics Summit for his session, “Is there anything GLP‑1s can’t do? Unlocking the next generation of metabolic treatments.” He will offer a fo...

14 Apr
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

ICON is once again sponsoring and presenting at #OCTEU26 on 6–7 May in Barcelona, which focuses on the evolving needs of the biotechnology sector within clinical research. The meeting highlights scientific innovation alo...

13 Apr
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

ICON is once again sponsoring and presenting at #OCTEU26 on 6–7 May in Barcelona, which focuses on the evolving needs of the biotechnology sector within clinical research. The meeting highlights scientific innovation alo...

13 Apr
4
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

Frequentist and Bayesian frameworks in NMA Different analytical paradigms offer different strengths. The whitepaper sets out the contrasting roles of frequentist regression based models and Bayesian hierarchical models,...

13 Apr
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

Frequentist and Bayesian frameworks in NMA Different analytical paradigms offer different strengths. The whitepaper sets out the contrasting roles of frequentist regression based models and Bayesian hierarchical models,...

13 Apr
2
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

ICON is proud to mark World Parkinson’s Day by highlighting the vital role of clinical research in advancing care for people living with Parkinson’s. Over the past 5 years, we have conducted 93 Neurodegeneration studie...

11 Apr
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

Selecting the right pediatric HRQoL instrument is no longer optional. It’s a regulatory expectation. Our latest blog breaks down a six criterion framework to guide sponsors in making defensible, patient focused choices, ...

10 Apr
3
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

In many neurodegenerative diseases, changes in the brain begin years before clinical signs emerge. New technologies and methods are enabling earlier diagnosis and intervention. Explore how pragmatic adoption of these inn...

10 Apr
2
View post
View webpage
  • Previous
  • 1
  • …
  • 2
  • 3
  • 4
  • …
  • 98
  • Next
Filter by:

Filter by:

Site Branding
    ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Webinars
Socials
  • Linkedin
  • Facebook
  • Instagram
  • Youtube

Legal Footer

  • © 2026 ICON plc
  • Disclaimer
  • Privacy & Data
  • Cookies
How can we help?
  • All
  • Website
Popular search terms:
  • Biotech
  • Cell and Gene Therapies
  • Consulting
  • Early Clinical
  • Medical Device
  • Oncology
  • Rare & Orphan Diseases
  • Real World Evidence
  • Site & Patient Recruitment
  • Strategic Solutions
  • Regulatory Intelligence